SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four investor conferences in the second quarter of 2024. Canaccord Genuity Horizons in Oncology Virtual ConferenceMonday, April 15, 202412:00pm PT/3:00pm ET JPM Securities Life Sciences Conference Tuesday, May 14, 2024 ...

Allogene Therapeutics, Inc. (ALLO) incurred an adjusted loss (excluding impairment of long-lived asset) of 43 cents per share in fourth-quarter 2023, narrower than the Zacks Consensus Estimate of a loss of 47 cents.Inclusive of impairment charges, the company posted a loss of 51 cents in the fourth quarter. In the year-ago quarter, the company reported a loss of 67 cents. There was no impairment charge recorded in the year-ago period.ALLO recorded revenues of $0.02 million during the quarter, missing the Za ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript March 14, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affairs and Brand Strategy Officer David Chang - President and Chief Executive Officer Zachary Roberts - Executive Vice President of Research and Development and Chief Medical Officer Geoff Parker - Chief financial officer Conference Call Participants Tyler Van Buren - TD Cowen Salveen Richter - Goldman Sachs Brian Cheng - JPMorgan Jack Allen - Baird ...

Allogene Therapeutics (ALLO) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.51%. A quarter ago, it was expected that this immuno-oncology company would post a loss of $0.53 per share when it actually produced a loss of $0.37, delivering a surprise of 30.19%.Over the last four quarters, the ...

Allogene Therapeutics (ALLO) announced that it has entered into a non-exclusive licensing agreement with privately-held Arbor Biotechnologies to utilize the latter’s proprietary CRISPR gene-editing technology.Allogene intends to utilize Arbor’s CRISPR technology with its own proprietary platform to develop next-generation allogeneic CAR T (AlloCAR T) therapies targeting autoimmune diseases (AID).However, neither of the companies disclosed any specific financial terms or considerations pertaining to the abov ...

Exhibit 99.1 Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update • Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL): Start-Up Activities Underway; Enrollment to Begin Mid-2024 • Cema-cel Phase 1 ALPHA2 Trial in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Enrolling Patients with Initial Data Projected YE 2024 • ALLO-329 in Autoimmune Disease (AID): Differentiated Next-Generation CD19 Dagger Program Design ...

Table of Contents | --- | --- | --- | |-------|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | _________________________________ Commission File Number | | | | Allogene Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) ____________________ ...

Allogene's AlloCAR T™ Autoimmune Disease Platform Leverages Arbor's CRISPR Gene-Editing TechnologyFirst Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune Disease Expected to Initiate in Early 2025 SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, and Arbor Biotechnologies, Inc. ("Arbor" ...

Allogene Therapeutics, Inc. (ALLO) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ALLO's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving avera ...

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report fourth quarter and full year 2023 financial results and provide a business update on March 14, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/ ...